share_log

三葉草生物(02197.HK)二價RSV候選疫苗I期臨床試驗 老年人群組獲積極初步數據

Phase I clinical trial of Three Leaves Bio's (02197.HK) bivalent RSV vaccine candidate shows positive preliminary data in elderly population group.

AASTOCKS ·  Jun 18 17:31

Triple Leaf Bio-B (02197.HK) announced that in the Phase I clinical trial of SCB-1019, a bivalent RSVPreF-trimer subunit candidate vaccine developed based on the company's unique Trimer-Tag (protein trimerization) vaccine technology platform, positive preliminary immunogenicity and safety data were obtained in the elderly group (60 to 85 years old). These preliminary data obtained in the elderly group are consistent with the positive data obtained in the young adult group (18-59 years old) announced by the company in April of this year.

In the ongoing Phase I clinical trial, 48 subjects in the elderly group were enrolled and received either SCB1019 or normal saline placebo.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment